Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Sarah Rochestie"'
6
453 Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma
Autor: Neil Cooch, Thomas U. Marron, Sarah Rochestie, Alfredo Perales-Puchalt, Joann Peters, Mark Yarchoan, Edward Gane, Niranjan Y. Sardesai, Ildiko Csiki
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundHepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death. Immune checkpoint inhibitors targeting PD-1 have limited activity in HCC as monotherapy, with response rates ranging from 14–17%. Tumor neoantigens de
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32bbb705342067d04c664badcd91f99a
https://doaj.org/article/6a68b03e77254ac39b3e7e0b17ff473a
Zobrazit plný text záznamu
7
Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma
Autor: Neil Cooch, Ildiko Csiki, Thomas U. Marron, Edward Gane, Sarah Rochestie, Joann Peters, Mark Yarchoan, Alfredo Perales-Puchalt, Niranjan Y. Sardesai
Publikováno v: Journal of Clinical Oncology. 39:TPS2680-TPS2680
TPS2680 Background: Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death. Immune checkpoint inhibitors targeting PD-1 have limited activity in HCC as monotherapy, with response rates ranging from 14-17%. Tumor neoant
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce0a55a703a3aba3295babc96e4fff0b
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2680
Zobrazit plný text záznamu
8
Personalized DNA neoantigen vaccine in combination with plasmid IL-12 for the treatment of a patient with anaplastic astrocytoma
Autor: Niranjan Y. Sardesai, Michael D. McLellan, Gavin P. Dunn, Alfredo Perales-Puchalt, S. Peter Goedegebuure, Jasreet Hundal, Roger Stupp, Chris Miller, William E. Gillanders, Tanner M. Johanns, Neil Cooch, Mitchel S. Berger, Sarah Rochestie, Joann Peters
Publikováno v: Journal of Clinical Oncology. 39:e14561-e14561
e14561 Background: Tumor neoantigens are epitopes derived from tumor-specific mutations that may be incorporated in personalized vaccines to prime T cell responses. DNA vaccines delivered with electroporation have recently shown strong CD8 and CD4 T
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2e8c85e42e95d7f0e6eddce200fe116
https://doi.org/10.1200/jco.2021.39.15_suppl.e14561
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje